000			01917 a2200493 4500
005			20250518090556.0
264		0	_c20210107
008			202101s 0 0 eng d
022			_a1873-5177
024	7		_a10.1016/j.pbb.2020.172891 _2doi
040			_aNLM _beng _cNLM
100	1		_aHaga, Hidaka
245	0	0	_aNovel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice. _h[electronic resource]
260			_bPharmacology, biochemistry, and behavior _c04 2020
300			_a172891 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine _xadverse effects
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xadministration & dosage
650	0	4	_aBlood-Brain Barrier _xdrug effects
650	0	4	_aCell Death _xdrug effects
650	0	4	_aCognitive Dysfunction _xdrug therapy
650	0	4	_aDisease Models, Animal
650	0	4	_aDopaminergic Neurons _xdrug effects
650	0	4	_aFatty Acid Binding Protein 3 _xmetabolism
650	0	4	_aLevodopa _xadministration & dosage
650	0	4	_aLigands
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMice, Inbred C57BL
650	0	4	_aMotor Activity _xdrug effects
650	0	4	_aNeuroprotective Agents _xadministration & dosage
650	0	4	_aParkinson Disease _xdrug therapy
650	0	4	_aProtein Aggregation, Pathological _xdrug therapy
650	0	4	_aalpha-Synuclein _xmetabolism
700	1		_aYamada, Ryo
700	1		_aIzumi, Hisanao
700	1		_aShinoda, Yasuharu
700	1		_aKawahata, Ichiro
700	1		_aMiyachi, Hiroyuki
700	1		_aFukunaga, Kohji
773	0		_tPharmacology, biochemistry, and behavior _gvol. 191 _gp. 172891
856	4	0	_uhttps://doi.org/10.1016/j.pbb.2020.172891 _zAvailable from publisher's website
999			_c30699807 _d30699807